Table 5 Demographic and clinical characteristics of patients divided in to clusters by Two Step Algorithm
Cluster-1 (n = 30) | Cluster-2 (n = 14) | p | |
|---|---|---|---|
Age (years) | 48 ± 11 | 54 ± 08 | 0.10 |
Male | 20 (66.7%) | 7 (50%) | 0.29 |
Primary renal diagnosis | |||
Hypertension | 8 (26.7%) | 3 (21.4%) | |
Diabetes | 0 (0%) | 11 (78.6%) | |
Glomerulonephritis | 8 (26.7%) | 0 (0%) | 0.001 |
Unknown cause | 7 (23.3%) | 0 (0%) | |
Others | 7 (23.3%) | 0 (0%) | |
Diabetes (n. %) | 0 (0%) | 14 (100%) | 0.0001 |
Prior Transplant | 2 (6.7%) | 0 (0%) | 0.32 |
Length of time on hemodialysis (months) | 28 [14–43] | 33 [17–47] | 0.51 |
Panel reactive antibody class I (%) | 0 [0–15] | 0 [0–0] | 0.33 |
Mismatches (n) | 3 [2–4] | 3 [2–3] | 0.20 |
Donor | |||
Deceased | 24 (80%) | 13 (92.9%) | 0.27 |
Living | 6 (20%) | 1 (7.1%) | |
Donor Age (years) | 40 ± 10 | 37 ± 13 | 0.40 |
Cause of Donor Death | |||
Cranial trauma | 9 (30%) | 6 (42%) | |
Cerebrovascular | 9 (30%) | 4 (28.5%) | |
Others | 7 (40%) | 4 (28.5%) | 0.90 |
Final donor creatinin (mg/dL) | 1.19 ± 0.6 | 1.14 ± 0.58 | 0.78 |
Cold ischemia time (hours) | 21.8 ± 7 | 23.2 ± 3.9 | 0.50 |
Induction therapy | |||
Basiliximab | 9 (30%) | 3 (21.4%) | 0.55 |
Thymoglobulin | 21 (70%) | 11 (78.6%) | |
Immunosuppression | |||
FK + MFS + PDN | 13 (43.3%) | 3 (21.4%) | |
FK + SRL + PDN | 4 (13%) | 1 (7.1%) | 0.22 |
FK + EVR + PDN | 13 (43.3%) | 10 (71.4%) | |
Use of ARB/ACEi | 17 (56.7%) | 9 (69.2%) | 0.43 |
Calcium (mg/dL) | 9.39 ± 0.80 | 9.04 ± 0.52 | 0.14 |
Phosphate (mg/dL) | 4.19 ± 1.78 | 4.5 ± 1.4 | 0.47 |
PTH (ng/dl) | 199 [117–499] | 211 [68–470] | 0.76 |
Hb (g/dl) | 10.8 ± 1.9 | 10.6 ± 1.7 | 0.72 |
SBP (mmHg) | 138 ± 25 | 139 ± 13 | 0.96 |
DBP (mmHg) | 85 ± 14 | 77 ± 12 | 0.07 |
LVMi (g/m2) | 83 ± 17 | 93 ± 19 | 0.02 |